Goldman Sachs’s Urovant Sciences Ltd. UROV Stock Holding History

Goldman Sachs’s Portfolio UROV Stock Details UROV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-18,140	Closed	-$172K	–	5490
2019 Q3	$172K	Buy	+18,140	New	+$157K	﹤0.01%	4857

Other funds holding UROV

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Goldman Sachs's UROV Position: Q4 2019 in Review

Goldman Sachs sold out of Urovant Sciences Ltd. (UROV) in Q4 2019, closing a stake of 18,140 shares — an estimated $172K sold.

Goldman Sachs first reported a position in UROV in Q3 2019 and held it in 1 quarter. The position peaked at $172K in Q3 2019. 25 funds tracked by Wall St. Rank hold UROV as of Q4 2019.

Goldman Sachs reported no remaining Urovant Sciences Ltd. position as of Q4 2019 after selling out during the quarter.
Goldman Sachs sold 18,140 Urovant Sciences Ltd. shares in Q4 2019, an estimated $172K.
Goldman Sachs first reported a position in Urovant Sciences Ltd. in Q3 2019 and held it in 1 quarter.
Goldman Sachs's Urovant Sciences Ltd. position peaked at $172K in Q3 2019.
25 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q4 2019.

Based on Goldman Sachs's 13F filing for Q4 2019, filed 14 Feb 2020.